التفاصيل البيبلوغرافية
| العنوان: |
Oral epigallocatechin-3-gallate for treatment of dystrophic epidermolysis bullosa: a multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial |
| المؤلفون: |
Chiaverini, Christine, Roger, Coralie, Fontas, Eric, Bourrat, Emmanuelle, Bourdon-Lanoy, Eva, Labrèze, Christine, Mazereeuw, Juliette, Vabres, Pierre, Bodemer, Christine, Lacour, Jean-Philippe |
| بيانات النشر: |
BioMed Central Ltd. |
| سنة النشر: |
2016 |
| المجموعة: |
BioMed Central |
| مصطلحات موضوعية: |
Dystrophic epidermolysis bullosa, Polyphenon, Green tea, Cathechin, Metalloproteinase |
| الوصف: |
Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genodermatosis with severe blistering. No curative treatment is available. Scientific data indicated that epigallocatechin-3-gallate (EGCG), a green tea extract, might improve the phenotype of RDEB patients. In a multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial, we evaluated a 4-month oral EGCG treatment regimen in 17 RDEB patients. We found that EGCG treatment was not more effective than placebo in modified intention to treat and per protocol analysis ( n = 16; p = 0.78 and n = 10; p = 1 respectively). Tolerance was good. Specific organizational and technical difficulties of controlled randomized double-blind trials in EB patients are discussed. Trial registration US National Institutes of Health Clinical Trial Register ( NCT00951964 ). |
| نوع الوثيقة: |
other non-article part of journal/newspaper |
| اللغة: |
English |
| العلاقة: |
http://www.ojrd.com/content/11/1/31Test |
| الإتاحة: |
http://www.ojrd.com/content/11/1/31Test |
| حقوق: |
Copyright 2016 Chiaverini et al. |
| رقم الانضمام: |
edsbas.696D95AA |
| قاعدة البيانات: |
BASE |
